SG11202011568XA - Treating multiple myeloma and the use of biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-4-yl)oxy)methyl)benzyl) piperazin-1-yl)-3-fluorobenzonitrile - Google Patents
Treating multiple myeloma and the use of biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-4-yl)oxy)methyl)benzyl) piperazin-1-yl)-3-fluorobenzonitrileInfo
- Publication number
- SG11202011568XA SG11202011568XA SG11202011568XA SG11202011568XA SG11202011568XA SG 11202011568X A SG11202011568X A SG 11202011568XA SG 11202011568X A SG11202011568X A SG 11202011568XA SG 11202011568X A SG11202011568X A SG 11202011568XA SG 11202011568X A SG11202011568X A SG 11202011568XA
- Authority
- SG
- Singapore
- Prior art keywords
- dioxopiperidin
- oxoisoindolin
- fluorobenzonitrile
- piperazin
- biomarkers
- Prior art date
Links
- 208000034578 Multiple myelomas Diseases 0.000 title 1
- YTINZZFBHWSAGL-UHFFFAOYSA-N O=C1NC(CCC1N1C(C2=CC=CC(=C2C1)OCC1=CC=C(CN2CCN(CC2)C2=C(C=C(C#N)C=C2)F)C=C1)=O)=O Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1)OCC1=CC=C(CN2CCN(CC2)C2=C(C=C(C#N)C=C2)F)C=C1)=O)=O YTINZZFBHWSAGL-UHFFFAOYSA-N 0.000 title 1
- 206010035226 Plasma cell myeloma Diseases 0.000 title 1
- 239000000090 biomarker Substances 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6866—Interferon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862675732P | 2018-05-23 | 2018-05-23 | |
US201862737772P | 2018-09-27 | 2018-09-27 | |
PCT/US2019/033520 WO2019226770A1 (fr) | 2018-05-23 | 2019-05-22 | Traitement du myélome multiple et utilisation de biomarqueurs pour le 4-(4-(4-(((2-(2,6-dioxopipéridin-3-yl)-1-oxoisoindolin-4-yl)oxy)méthyl)benzyl)pipérazin-1-yl)-3-fluorobenzonitrile |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202011568XA true SG11202011568XA (en) | 2020-12-30 |
Family
ID=68614443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202011568XA SG11202011568XA (en) | 2018-05-23 | 2019-05-22 | Treating multiple myeloma and the use of biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-4-yl)oxy)methyl)benzyl) piperazin-1-yl)-3-fluorobenzonitrile |
Country Status (12)
Country | Link |
---|---|
US (3) | US10969381B2 (fr) |
EP (1) | EP3796909A4 (fr) |
JP (1) | JP7495886B2 (fr) |
KR (1) | KR20210024454A (fr) |
CN (1) | CN112492874A (fr) |
AU (1) | AU2019272751A1 (fr) |
BR (1) | BR112020023756A2 (fr) |
CA (1) | CA3101174A1 (fr) |
IL (1) | IL278854A (fr) |
MX (1) | MX2020012548A (fr) |
SG (1) | SG11202011568XA (fr) |
WO (1) | WO2019226770A1 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112021013435A2 (pt) * | 2019-01-09 | 2021-10-19 | Celgene Corporation | Formas sólidas que compreendem (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-4-il)oxi)metil)benzil)piperazin-1-il)-3-fluorobenzonitrila e sais do mesmo, e composições que compreendem e métodos de uso do mesmo |
WO2020146441A1 (fr) | 2019-01-09 | 2020-07-16 | Celgene Corporation | Compositions pharmaceutiques comprenant du (s)-4-(4-(4-(((2-(2,6-dioxopipéridin-3-yl)-1-oxoisoindolin-4-yl)oxy)méthyl)benzyl)pipérazin-1-yl)-3-fluorobenzonitrile et leurs méthodes d'utilisation |
CA3168456A1 (fr) * | 2020-01-20 | 2021-07-29 | Kangpu Biopharmaceuticals, Ltd. | Derive d'isoindoline, composition pharmaceutique et son utilisation |
KR102555483B1 (ko) * | 2020-06-29 | 2023-07-14 | 고려대학교 산학협력단 | 다발골수종에서 혈액 표지자를 이용한 세레블론 발현 예측 방법 |
CN115916768A (zh) | 2020-07-20 | 2023-04-04 | 江苏恒瑞医药股份有限公司 | 含硫异吲哚啉类衍生物、其制备方法及其在医药上的应用 |
WO2023081735A1 (fr) * | 2021-11-03 | 2023-05-11 | Celgene Corporation | Récepteurs antigéniques chimériques spécifiques de l'antigène de maturation des cellules b destinés à être utilisés dans le traitement d'un myélome |
WO2023138647A1 (fr) * | 2022-01-19 | 2023-07-27 | 江苏恒瑞医药股份有限公司 | Forme cristalline d'un dérivé d'isoindoline contenant du soufre |
WO2024025968A1 (fr) * | 2022-07-28 | 2024-02-01 | Springworks Therapeutics, Inc. | Traitement du myélome multiple |
WO2024059494A1 (fr) * | 2022-09-12 | 2024-03-21 | Celgene Corporation | Méthodes de traitement d'un myélome multiple |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
ATE205542T1 (de) | 1992-03-04 | 2001-09-15 | Univ California | Vergleichende genomhybridisierung |
US5714615A (en) * | 1994-02-08 | 1998-02-03 | Georgia Tech Research Corporation | Pyridinium compounds |
DE4441676A1 (de) * | 1994-11-23 | 1996-05-30 | Basf Ag | Iminooxymethylenanilide, Verfahren zu ihrer Herstellung und ihre Verwendung |
US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
US5948893A (en) | 1996-01-17 | 1999-09-07 | The United States Of America As Represented By The Secretary Of The Navy | Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody |
US6207157B1 (en) | 1996-04-23 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for nontypeable Haemophilus influenzae |
US6927024B2 (en) | 1998-11-30 | 2005-08-09 | Genentech, Inc. | PCR assay |
EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
EP2829609A1 (fr) | 1999-08-24 | 2015-01-28 | E. R. Squibb & Sons, L.L.C. | Anticorps CTLA-4 humains et leurs utilisations |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
AU3074001A (en) | 1999-12-09 | 2001-06-18 | Advanced Research And Technology Institute, Inc. | Fluorescent in situ rt-pcr |
CA2439402A1 (fr) | 2001-03-02 | 2002-09-12 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Procede de reaction en chaine de la polymerase |
CA2466279A1 (fr) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents modulant l'activite de cellules immunes et procedes d'utilisation associes |
AU2003288675B2 (en) | 2002-12-23 | 2010-07-22 | Medimmune Limited | Antibodies against PD-1 and uses therefor |
US7122799B2 (en) | 2003-12-18 | 2006-10-17 | Palo Alto Research Center Incorporated | LED or laser enabled real-time PCR system and spectrophotometer |
JP4361545B2 (ja) | 2005-05-09 | 2009-11-11 | 小野薬品工業株式会社 | ProgrammedDeath1(PD−1)に対するヒトモノクローナル抗体および抗PD−1抗体単独または他の免疫療法と併用した癌治療方法 |
HUE026039T2 (en) | 2005-07-01 | 2016-05-30 | Squibb & Sons Llc | Human monoclonal antibodies programmed for death ligand 1 (PD-L1) |
PL2170959T3 (pl) | 2007-06-18 | 2014-03-31 | Merck Sharp & Dohme | Przeciwciała przeciwko ludzkiemu receptorowi programowanej śmierci PD-1 |
EP2262837A4 (fr) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | Protéines de liaison avec pd-1 |
KR101924874B1 (ko) | 2008-09-26 | 2018-12-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-pd-1, pd-l1, 및 pd-l2 항체 및 그의 용도 |
JP5603876B2 (ja) | 2008-10-29 | 2014-10-08 | セルジーン コーポレイション | 癌の治療に使用するためのイソインドリン化合物 |
EP2376535B9 (fr) | 2008-12-09 | 2017-09-13 | F. Hoffmann-La Roche AG | Anticorps anti-pd-l1 et leur utilisation pour améliorer la fonction des lymphocytes t |
EP2393835B1 (fr) | 2009-02-09 | 2017-04-05 | Université d'Aix-Marseille | Anticorps contre pd-1 et anticorps contre pd-l1 et leurs utilisations |
JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Pd−l1/pd−l2の同時阻害 |
US20130022629A1 (en) | 2010-01-04 | 2013-01-24 | Sharpe Arlene H | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof |
CA2802344C (fr) | 2010-06-18 | 2023-06-13 | The Brigham And Women's Hospital, Inc. | Anticorps di-specifiques anti-tim-3 et pd-1 pour immunotherapie dans des etats pathologiques immuns chroniques |
US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
MX2015001686A (es) * | 2012-08-09 | 2015-04-10 | Celgene Corp | Tratamiento de enfermedades inmuno - relacionadas e inflamatorias. |
WO2014028445A2 (fr) | 2012-08-14 | 2014-02-20 | Celgene Corporation | Isoformes de céréblon et leur utilisation en tant que biomarqueurs pour traitement thérapeutique |
US9587281B2 (en) * | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
WO2015085172A2 (fr) * | 2013-12-06 | 2015-06-11 | Celgene Corporation | Méthodes de détermination de l'efficacité pharmacologique du traitement du lymphome diffus à grandes cellules b, du myélome multiple et des cancers myéloïdes |
CN108055853A (zh) * | 2014-10-10 | 2018-05-18 | 达纳-法伯癌症研究所有限公司 | 包括内部核糖体进入位点的质粒和其用途 |
JP2017533727A (ja) * | 2014-10-13 | 2017-11-16 | セルジーン コーポレイション | 固形腫瘍の治療方法及び免疫調節療法への臨床的感度の予測因子としてのバイオマーカーの使用 |
AU2016258914A1 (en) * | 2015-05-01 | 2017-11-09 | Guardant Health, Inc. | Diagnostic methods |
MX2018008421A (es) * | 2016-01-08 | 2019-12-09 | Celgene Corp | Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias. |
AU2018301335B2 (en) * | 2017-07-10 | 2022-09-15 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
EP3796912B1 (fr) | 2018-05-23 | 2023-02-15 | Celgene Corporation | Composés antiprolifératifs et anticorps bispécifique contre bcma et cd3 pour une utilisation combinée |
-
2019
- 2019-05-22 AU AU2019272751A patent/AU2019272751A1/en active Pending
- 2019-05-22 CA CA3101174A patent/CA3101174A1/fr active Pending
- 2019-05-22 MX MX2020012548A patent/MX2020012548A/es unknown
- 2019-05-22 SG SG11202011568XA patent/SG11202011568XA/en unknown
- 2019-05-22 CN CN201980048256.0A patent/CN112492874A/zh active Pending
- 2019-05-22 EP EP19807950.1A patent/EP3796909A4/fr active Pending
- 2019-05-22 JP JP2020565470A patent/JP7495886B2/ja active Active
- 2019-05-22 WO PCT/US2019/033520 patent/WO2019226770A1/fr unknown
- 2019-05-22 US US16/420,031 patent/US10969381B2/en active Active
- 2019-05-22 BR BR112020023756-6A patent/BR112020023756A2/pt unknown
- 2019-05-22 KR KR1020207034893A patent/KR20210024454A/ko not_active Application Discontinuation
-
2020
- 2020-11-20 IL IL278854A patent/IL278854A/en unknown
-
2021
- 2021-02-10 US US17/173,176 patent/US11726080B2/en active Active
-
2023
- 2023-06-29 US US18/216,405 patent/US20230341375A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3796909A1 (fr) | 2021-03-31 |
BR112020023756A2 (pt) | 2021-02-09 |
US20230341375A1 (en) | 2023-10-26 |
US10969381B2 (en) | 2021-04-06 |
KR20210024454A (ko) | 2021-03-05 |
MX2020012548A (es) | 2021-05-13 |
JP7495886B2 (ja) | 2024-06-05 |
US20210181184A1 (en) | 2021-06-17 |
EP3796909A4 (fr) | 2022-03-16 |
IL278854A (en) | 2021-01-31 |
US11726080B2 (en) | 2023-08-15 |
JP2021525362A (ja) | 2021-09-24 |
CA3101174A1 (fr) | 2019-11-28 |
AU2019272751A1 (en) | 2020-12-10 |
US20190361005A1 (en) | 2019-11-28 |
WO2019226770A1 (fr) | 2019-11-28 |
CN112492874A (zh) | 2021-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL278854A (en) | Treatment of multiple myeloma and the use of biomarkers for 4-(4-(4-(((2-(6,2-dioxopyridin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazine-1 -yl-3-fluorobenzonitrile | |
MX2023000085A (es) | Compuestos antiproliferativos y metodos para utilizarlos. | |
IL304534A (en) | kras g12c inhibitors | |
MX2022000249A (es) | Formas cristalinas de un inhibidor de magl. | |
MX2017009892A (es) | Agente terapeutico contra el colangiocarcinoma. | |
IL287030A (en) | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide as raf inhibitors for cancer therapy | |
IL252368B (en) | 2-(5,1-dimethyl-3-phenyl-h1-pyrrol-2-yl)-n-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2- Oxacetamide and pharmaceutical preparations containing it | |
SI3644999T1 (sl) | Sestavki in postopki uporabe 2-(4-klorofenil)-N-((2-(2,6-dioksopiperidin-3-il)-1-oksoizoindolin-5-il) metil)-2,2-difluoroacetamida | |
SA515360022B1 (ar) | أملاح وصور صلبة من المركب (s) ــ 3 ــ(4 ــ((4ــ(مورفولينو ميثيل)بنزيل)أوكسي)-1-أوكسو أيزو إندولين-2-يل)ببريدين-2 ،6-دايون، وتركيبات تشتمل عليها، وطرق استخدامها | |
IL284680A (en) | Solid forms including (S) -4-(4-(4 - (((2-(2,6-dioxopyridin-3-YL)-1-oxoisindin-4-YL)oxy)methyl)benzyl)PIPERAZIN-1- YL)-3-Fluorobenzityl and salts thereof, and the overall compositions and methods of using the same | |
ZA201804482B (en) | Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide | |
PL3464276T3 (pl) | Nowa postać krystaliczna n-[5-(3,5-difluoro-benzylo)-1h-indazol-3-ilo)-4-(4-metylopiperazyn-1-ylo)-2-tetrahydropiran-4-yloamino)-benzamidu | |
EP3735243A4 (fr) | Isotopologues de 2-(4-chlorophényl)-n-((2-(2,6-dioxopipéridin-3-yl)-1-oxoisoindolin-5-yl)méthyl)-2,2-difluoroacétamide | |
IL284509A (en) | Compounds and methods of use of 2-(4-chlorophenyl)-N-((2-(26-deoxypyricin-3-yl)-1-(oxoisoindolin-5-yl)meranyl)-2,2-difluoroacetamide | |
EP4048668A4 (fr) | Méthodes de traitement d'un cancer hématologique et utilisation de biomarqueurs compagnons pour 2-(2,6-dioxopipéridin-3-yl)-4-((2-fluoro-4-((3-morpholinoazétidin-1-yl)méthyl)benzyl)amino)isoindoline-1,3-dione | |
EP4054578A4 (fr) | Polythérapie avec le 2-(4-chlorophényl)-n-((2-(2,6-dioxopipéridin-3-yl)-1-oxoisoindolin-5-yl)méthyl)-2,2-difluoroacétamide | |
PH12020551465A1 (en) | Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds | |
IL284665A (en) | Pharmaceutical compounds consisting of (S)-4- (4- (4- (((2- (2,6-dioxopyridin-3-yl)-1-oxoisoinolin-4-yl)oxy)methyl)benzyl)piperazine-1- YL)-3-fluorobenzonitrile and methods of using the same | |
ZA201801544B (en) | 1-(4-(2-((1-(3,4-difluorophenyl)-1h-pyrazol-3-yl)methoxy)ethyl) piperazin-1-yl)ethanone salts | |
MX2020002083A (es) | Composicion farmaceutica que comprende un inhibidor tirosina cinasa selectivo para receptores del factor de crecimiento de fibroblastos (fgfr). |